NDAORALTABLET
Approved
Sep 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYCLAPEN-W (cyclacillin) is an oral beta-lactam antibiotic approved in 1979 for bacterial infections. It is a semisynthetic penicillin derivative administered as tablets. The drug targets susceptible gram-positive and gram-negative bacteria through inhibition of bacterial cell wall synthesis.
LOE Approaching
Competitive pressure remains moderate (30/100) but product is approaching loss of exclusivity, signaling a contracting team and shift toward defensive strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CYCLAPEN-W offers limited growth trajectory given its mature lifecycle and approaching LOE; roles focus on managing declining market share and optimizing profitability rather than innovation. Career development is constrained by minimal linked job openings (0 identified) and the defensive nature of end-of-life portfolio management.
Brand ManagerField Sales Representative
Worked on CYCLAPEN-W at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.